Literature DB >> 22670582

Renal denervation and treatment of hypertension.

Ralph Knöll1.   

Abstract

Cardiovascular diseases kill more people each year than any other diseases. In 2008, 7.3 million people died of ischaemic heart disease, 6.2 million from stroke or another form of cerebrovascular disease. Hypertension affects about 1 billion people worldwide and is a major risk factor for many cardiovascular diseases, including coronary heart disease and stroke. In contrast, our knowledge in regard to the underlying molecular mechanisms remains incomplete and, as a consequence, it is difficult if not impossible to efficiently treat the most affected patients. While the development and application of novel pharmacological agents in combination with lifestyle changes have been applied in Western developed countries to a large number of patients, a significant number of individuals fail to respond. Recently, several novel approaches have been developed including a minimally invasive catheter-based renal nerve ablation technique and some of the consequences will be highlighted in this brief review article. This will include the discussion of previous attempts to denervate the renal arteries as well as the significant improvements achieved when catheter-based interventions are applied.

Entities:  

Mesh:

Year:  2012        PMID: 22670582     DOI: 10.2165/11593680-000000000-00000

Source DB:  PubMed          Journal:  High Blood Press Cardiovasc Prev        ISSN: 1120-9879


  35 in total

1.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.

Authors:  Murray D Esler; Henry Krum; Paul A Sobotka; Markus P Schlaich; Roland E Schmieder; Michael Böhm
Journal:  Lancet       Date:  2010-11-17       Impact factor: 79.321

Review 2.  Neurogenic factors and hypertension in chronic renal failure.

Authors:  V M Campese
Journal:  J Nephrol       Date:  1997 Jul-Aug       Impact factor: 3.902

3.  Mechanism of elevated plasma noradrenaline in the course of essential hypertension.

Authors:  M Esler; G Jennings; B Biviano; G Lambert; G Hasking
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

4.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

5.  Renal denervation attenuates the sodium retention and hypertension associated with obesity.

Authors:  S Kassab; T Kato; F C Wilkins; R Chen; J E Hall; J P Granger
Journal:  Hypertension       Date:  1995-04       Impact factor: 10.190

6.  The effect of renal denervation on ACTH-induced hypertension in sheep.

Authors:  J A Whitworth; D A Denton; W F Graham; T J Humphery; B A Scoggins; J P Coghlan
Journal:  Clin Exp Pharmacol Physiol       Date:  1981 May-Jun       Impact factor: 2.557

7.  Decrease in peripheral sympathetic nervous system activity following renal denervation or unclipping in the one-kidney one-clip Goldblatt hypertensive rat.

Authors:  R E Katholi; S R Winternitz; S Oparil
Journal:  J Clin Invest       Date:  1982-01       Impact factor: 14.808

8.  A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial.

Authors:  Michael A Weber; Henry Black; George Bakris; Henry Krum; Stuart Linas; Robert Weiss; Jennifer V Linseman; Brian L Wiens; Marshelle S Warren; Lars H Lindholm
Journal:  Lancet       Date:  2009-09-11       Impact factor: 79.321

9.  Role of renal nerves in sodium retention of cirrhosis and congestive heart failure.

Authors:  G F DiBona; L L Sawin
Journal:  Am J Physiol       Date:  1991-02

10.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.

Authors:  Henry Krum; Markus Schlaich; Rob Whitbourn; Paul A Sobotka; Jerzy Sadowski; Krzysztof Bartus; Boguslaw Kapelak; Anthony Walton; Horst Sievert; Suku Thambar; William T Abraham; Murray Esler
Journal:  Lancet       Date:  2009-03-28       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.